Jain Global’s Verve Therapeutics VERV Stock Holding History

Jain Global’s Portfolio VERV Stock Details VERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-19,395	Closed	-$109K	–	1367
2024 Q4	$109K	Buy	+19,395	New	+$109K	﹤0.01%	688

Other funds holding VERV

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Jain Global's VERV Position: Q1 2025 in Review

Jain Global sold out of Verve Therapeutics (VERV) in Q1 2025, closing a stake of 19,395 shares — an estimated $109K sold.

Jain Global first reported a position in VERV in Q4 2024 and held it in 1 quarter. The position peaked at $109K in Q4 2024. 191 funds tracked by Wall St. Rank hold VERV as of Q1 2025.

Jain Global reported no remaining Verve Therapeutics position as of Q1 2025 after selling out during the quarter.
Jain Global sold 19,395 Verve Therapeutics shares in Q1 2025, an estimated $109K.
Jain Global first reported a position in Verve Therapeutics in Q4 2024 and held it in 1 quarter.
Jain Global's Verve Therapeutics position peaked at $109K in Q4 2024.
191 funds tracked by Wall St. Rank held Verve Therapeutics as of Q1 2025.

Based on Jain Global's 13F filing for Q1 2025, filed 15 May 2025.